MedTrace Logo

A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703

NCT01982747 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-05-19

No results posted yet for this study

Summary

MGN1703 is being developed for use in treating cancerous tumors effecting the colon, skin, kidneys and lungs. The dosage form of MGN1703 under investigation is an injection.

The goal of this study is to evaluate the effects of MGN1703 on the electrical activity of the heart in healthy subjects and to look at general safety.

Conditions

  • Healthy

Interventions

DRUG

MGN-Placebo

DRUG

Placebo-MGN

Sponsors & Collaborators

  • Mologen AG

    lead INDUSTRY

Principal Investigators

  • Carlos R Sanabria, MD · Spaulding Clinical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01982747 on ClinicalTrials.gov